We examined the binding of [
3H]U-46619, a thromboxane A
2 agonist, to human and guinea pig platelets and the binding of [
3H]SQ 29, 548, a thromboxane A
2 antagonist, to human, rat and guinea pig platelets. KW-3635 (sodium (
E)-11-[2-(5, 6-dimethyl-l-benzimidazolyl)ethylidene]-6, 11-dihydrodibenz[
b,
e]oxepin-2-carboxylate monohydrate) concentration-dependently inhibited the [
3H]U-46619 binding to human and guinea pig platelets with inhibition constants of 1.2 nM and 2.7 nM, respectively. KW-3635 also potently inhibited the [
3H]SQ 29, 548 binding to human and guinea pig platelets with inhibition constants of 1.9 nM and 3.2 nM, respectively. In contrast, KW-3635 was less active against thromboxane A
2/prostaglandin H
2 receptors in rat platelets with an inhibition constant of 97 nM. KW-3635 at 10
-5 M did not antagonize various receptors including prostaglandin E
2, prostaglandin I
2 and neurotransmitters. In addition, 10
-5 M KW-3635 did not alter the prostaglandin D
2-induced cAMP accumulation in EBTr cells. KW-3635 was inactive towards thromboxane synthase, cyclooxygenase and prostaglandin I
2 synthase up to 10
-5 M. KW-3635 slightly inhibited 5-lipoxygenase with an IC
50 value of 71 μM. These data indicate that KW-3635 is a potent and selective non-prostanoic thromboxane A
2 antagonist, and it can recognize the species differences in thromboxane A
2/prostaglandin H
2 receptors.
View full abstract